tiprankstipranks
Generate Biomedicines, Inc. (GENB)
NASDAQ:GENB
US Market
GENB
Generate Biomedicines, Inc.
RESEARCH TOOLSreports
Want to see GENB full AI Analyst Report?

Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Target

18 Followers
See the Price Targets and Ratings of:

GENB Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Generate
Biomedicines, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GENB Stock 12 Month Forecast

Average Price Target

$25.40
▲(104.02% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Generate Biomedicines, Inc. in the last 3 months. The average price target is $25.40 with a high forecast of $30.00 and a low forecast of $22.00. The average price target represents a 104.02% change from the last price of $12.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","16":"$16","21":"$21","26":"$26","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16,21,26,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,14.446153846153846,15.742307692307692,17.03846153846154,18.334615384615386,19.630769230769232,20.926923076923078,22.223076923076924,23.51923076923077,24.815384615384616,26.111538461538462,27.407692307692308,28.703846153846158,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,14.092307692307692,15.034615384615385,15.976923076923077,16.91923076923077,17.861538461538462,18.803846153846152,19.746153846153845,20.68846153846154,21.630769230769232,22.573076923076922,23.515384615384612,24.457692307692305,{"y":25.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,13.830769230769231,14.511538461538462,15.192307692307693,15.873076923076923,16.553846153846155,17.234615384615385,17.915384615384617,18.596153846153847,19.276923076923076,19.95769230769231,20.638461538461538,21.31923076923077,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.65,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$25.40Lowest Price Target$22.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on GENB
Sean Laaman
Morgan Stanley
Morgan Stanley
$20→$22
Buy
76.71%
Upside
Reiterated
05/14/26
Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley
H.C. Wainwright Analyst forecast on GENB
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
100.80%
Upside
Assigned
05/08/26
Generate Biomedicines price target raised to $25 from $16 at H.C. WainwrightGenerate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
Piper Sandler Analyst forecast on GENB
Edward Tenthoff
Piper Sandler
Piper Sandler
$24
Buy
92.77%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
Goldman Sachs Analyst forecast on GENB
Salveen Richter
Goldman Sachs
Goldman Sachs
$26
Buy
108.84%
Upside
Reiterated
04/09/26
Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
Guggenheim Analyst forecast on GENB
Seamus Fernandez
Guggenheim
Guggenheim
$30
Buy
140.96%
Upside
Initiated
03/24/26
Generate Biomedicines initiated with a Buy at GuggenheimGenerate Biomedicines initiated with a Buy at Guggenheim
Cantor Fitzgerald Analyst forecast on GENB
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
03/24/26
Generate Biomedicines initiated with an Overweight at Cantor FitzgeraldGenerate Biomedicines initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on GENB
Sean Laaman
Morgan Stanley
Morgan Stanley
$20→$22
Buy
76.71%
Upside
Reiterated
05/14/26
Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley
H.C. Wainwright Analyst forecast on GENB
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
100.80%
Upside
Assigned
05/08/26
Generate Biomedicines price target raised to $25 from $16 at H.C. WainwrightGenerate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
Piper Sandler Analyst forecast on GENB
Edward Tenthoff
Piper Sandler
Piper Sandler
$24
Buy
92.77%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
Goldman Sachs Analyst forecast on GENB
Salveen Richter
Goldman Sachs
Goldman Sachs
$26
Buy
108.84%
Upside
Reiterated
04/09/26
Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
Guggenheim Analyst forecast on GENB
Seamus Fernandez
Guggenheim
Guggenheim
$30
Buy
140.96%
Upside
Initiated
03/24/26
Generate Biomedicines initiated with a Buy at GuggenheimGenerate Biomedicines initiated with a Buy at Guggenheim
Cantor Fitzgerald Analyst forecast on GENB
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
03/24/26
Generate Biomedicines initiated with an Overweight at Cantor FitzgeraldGenerate Biomedicines initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the General Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Generate Biomedicines, Inc.

3 Months
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+22.00%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.00% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
2/2 ratings generated profit
100%
Average Return
+22.00%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.00% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+22.00%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +22.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GENB Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
3
4
6
Buy
0
0
2
3
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
5
7
10
In the current month, GENB has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GENB average Analyst price target in the past 3 months is 25.40.
Each month's total comprises the sum of three months' worth of ratings.

GENB Financial Forecast

GENB Earnings Forecast

Next quarter’s earnings estimate for GENB is -$0.51 with a range of -$0.56 to -$0.44. The previous quarter’s EPS was -$1.07. GENB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year GENB has its overall industry.
Next quarter’s earnings estimate for GENB is -$0.51 with a range of -$0.56 to -$0.44. The previous quarter’s EPS was -$1.07. GENB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year GENB has its overall industry.

GENB Sales Forecast

Next quarter’s sales forecast for GENB is $5.28M with a range of $0.00 to $7.22M. The previous quarter’s sales results were $7.22M. GENB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year GENB has its overall industry.
Next quarter’s sales forecast for GENB is $5.28M with a range of $0.00 to $7.22M. The previous quarter’s sales results were $7.22M. GENB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year GENB has its overall industry.

GENB Stock Forecast FAQ

What is GENB’s average 12-month price target, according to analysts?
Based on analyst ratings, Generate Biomedicines, Inc.’s 12-month average price target is 25.40.
    What is GENB’s upside potential, based on the analysts’ average price target?
    Generate Biomedicines, Inc. has 104.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GENB a Buy, Sell or Hold?
          Generate Biomedicines, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Generate Biomedicines, Inc.’s price target?
            The average price target for Generate Biomedicines, Inc. is 25.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $22.00. The average price target represents 104.02% Increase from the current price of $12.45.
              What do analysts say about Generate Biomedicines, Inc.?
              Generate Biomedicines, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of GENB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.